Divis Laboratories Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Divis Laboratories demonstrates robust performance with FY25 revenue of Rs 9,360 crore and a net profit of Rs 2,191 crore. The stock shows strong bullish momentum, trading above key moving averages, with a target price of ₹7,125–₹7,140.

Divis Laboratories Reports Strong Earnings and Bullish Momentum - 10 Jul, 2025

Divis Laboratories shares surged to a new 52-week high following HSBC's upgrade to Buy and a target price increase to ₹7,900. The company reported strong Q4FY25 earnings, with significant growth expected in peptides and contrast media. Analysts project a robust revenue potential by 2030, enhancing Divis' market position.

Divis Laboratories Hits New High on HSBC Upgrade - 08 Jul, 2025

Divis Laboratories is experiencing a strong uptrend, with a breakout at Rs 6,800. Analysts suggest potential upside to Rs 7,200, supported by bullish indicators.

Divis Laboratories Shows Strong Bullish Momentum - 02 Jul, 2025

Divis Laboratories Limited has announced the closure of its trading window from July 1, 2025, until 48 hours after its quarterly financial results are released. This is a routine measure to ensure compliance with insider trading regulations.

Divis Laboratories Announces Trading Window Closure - 30 Jun, 2025

Divis Laboratories, along with Syngene and Neuland, has noted that some requests for quotes (RFQs) are being converted into actionable projects, although substantial financial benefits will take time to materialize.

Divis Laboratories Sees RFQs Turning into Projects - 25 Jun, 2025

Divis Laboratories' shares are in focus following the settlement between Novartis and MSN regarding the Entresto patent. This development may lead to upward revisions in Divis' financial estimates for FY26 and FY27, depending on future litigation outcomes.

Divis Laboratories Gains from Novartis-MSN Patent Settlement - 18 Jun, 2025

Divis Laboratories Ltd is up 1.02% at Rs 6742, marking its third consecutive session of gains. The stock has risen 51.43% over the past year, outperforming both NIFTY and Nifty Pharma index. It has gained 13.46% in the last month, with trading volume at 3.53 lakh shares today.

Divis Laboratories Continues Upward Trend - 11 Jun, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

Foreign Institutions have increased holdings from 17.99% to 18.01% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

Revenue is up for the last 2 quarters, 2.40K Cr → 2.67K Cr (in ₹), with an average increase of 10.1% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 6 months, DIVISLAB stock has moved up by 19.4%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Netprofit is up for the last 4 quarters, 430.0 Cr → 662.0 Cr (in ₹), with an average increase of 13.4% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Mutual Funds have increased holdings from 11.89% to 12.83% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.0% return, outperforming this stock by 41.7%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 51.89% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Retail Investor have decreased holdings from 9.59% to 9.39% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

S&P BSE SEN. N50

Nifty Next 50

S&P BSE 100 ESG

BSE MFG

NIFTY 100

Nifty100 Eq Weig

S&P BSE Momentum

BSE 500

Nifty Healthcare

NIFTY PHARMA

Nifty 500

Nifty Alpha 50

Nifty100 Quality

BSE 200

BSE Healthcare

S&P BSE Largecap

S&P BSE Dividend Stability

S&P BSE 100 LargeCap TMC

Nifty LargeMidcap 250

S&P BSE 250 LargeMidCap

Nifty 200

BSE 100

SBI Equity Hybrid Fund Direct Growth

SBI Large Cap Fund Direct Growth

SBI Focused Fund Direct Plan Growth

Nippon India Pharma Fund - Direct Plan - Growth Plan

Axis ELSS Tax Saver Fund Direct Plan Growth Option

Divis Laboratories Ltd’s net profit jumped 23.05% since last year same period to ₹662.00Cr in the Q4 2024-2025. On a quarterly growth basis, Divis Laboratories Ltd has generated 12.39% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-1.15	Bullish
CCI (20)	401.91	Bearish
RSI (14)	44.25	Neutral
Momentum (10)	2.5	Bullish
ADI (14)	29.16	Bearish
Ultimate Oscillator (7,14,28)	30.94	Neutral

Name	Value	Action
SMA (20)	6835.45	Bullish
EMA (20)	6837.19	Bearish
VWMA (20)	6836.42	Bearish
SMA (50)	6842.91	Bearish
EMA (50)	6842.66	Bearish
SMA (200)	6864.89	Bearish
EMA (200)	6859.78	Bearish
KAMA (200)	6838.7	Bearish
DEMA (200)	6847.88	Bearish

Divis Laboratories Ltd (DIVISLAB)

Summary

Overall

Oscillators

Moving Averages